Dr. Rebecca Carriere
Dr. Rebecca Carriere is a Psychiatrist with 10 years of clinical experience. She has worked as the Ambulatory Mental Health Division Head at Trillium Health Partners in Mississauga. She is an Assistant Professor with the University of Toronto and has been the Postgraduate Site Education Director for Psychiatry at Trillium. She completed her medical degree at McMaster University and her Psychiatry Residency through the University of Toronto. In addition to her work at Toronto Ketamine Clinic, she works at Trillium’s Insight Health Solutions WSIB First Responders Mental Health Program.
Dr. Kyle Waldman
Head of Anesthesia
Dr. Kyle Waldman is a board-certified Anesthesiologist who completed his medical training and residency at the University of Toronto. In addition to his medical training, he holds a Master’s in Quality Improvement and Patient Safety from the Dalla Lana School of Public Health.
His clinical areas of interest include regional anesthesia and the use of multimodal analgesia to prevent persistent and chronic postoperative surgical pain. He has extensive experience in providing and designing state-of-the-art regional anesthesia programs and techniques to ensure optimal patient comfort.
Dr. Waldman also teaches anesthesiology residents from Queen’s University and the University of Toronto, where he holds the title of Assistant Professor and Lecturer, respectively.
Dr. Jack Barkin
Senior Medical Advisor
He is a Fellow of the American College of Surgeons (FACS), a Fellow of the Royal College of Surgeons of Canada (FRCS), a Fellow of the International College of Surgeons (FICS) and a Diplomate of the American Board of Urology (DABU).
Dr. Barkin also has a Masters in Health Care Management and is one of a few Certified Canadian Physician Executives, which recognizes physician leadership and excellence. He is a founding partner and Medical Director at Toronto-based Can-Am HIFU (High Intensity Focused Ultrasound) prostate-cancer treatment clinic.
Dr. Barkin has been involved in clinical research for more than 25 years and has been the principal investigator in over 250 Canadian and international clinical drug trials. He served on numerous medical advisory boards and has been published extensively in medical journals.
Dr. Paul Garfinkel
Psychiatrist and Former CEO, Centre for Addiction and Mental Health, professor in Psychiatry at University of Toronto; Advisor
Dr. Garfinkel serves on the Discipline Committee for the College of Physicians and Surgeons of Ontario, and was on the Governing Council for the Canadian Institutes of Health Research until 2018, chairing the latter’s Ethics Committee.
A researcher, clinician and administrator, Dr. Garfinkel is the author and editor of several books on eating disorders, as well as contributing over 150 peer reviewed articles more than 80 book chapters to the professional literature. He has taken a leading role in the advocacy of support for psychiatric science, professional education, and public education, fighting the stigma of mental illness and addiction and mentoring of younger scientists in psychiatric research.
In 1996, Dr. Garfinkel was elected to Fellowship in the Royal Society of Canada. In 2000, he received the Lifetime Achievement Award from the Academy for Eating Disorders. He received the Pacesetter Award from the Schizophrenia Society of Canada in 2004 and a Public Service Award from the Canadian Mental Health Association in 2009. The City of Toronto named a park, the Paul E. Garfinkel Park, in recognition of his service to the City, in 2009. He became an Officer of the Order of Canada in 2008.
Founder and CEO. Entrepreneur and Former Depression sufferer
Davies has, over the past 20 years, experienced the despair of treatment-resistant depression. It wasn’t until he was introduced to IV Ketamine infusions in the U.S. that he experienced both immediate relief and a resurgence of a range of emotions that were otherwise unavailable. Having gone through a myriad of partially- to completely-ineffective treatments, he can personally testify to the effectiveness of ketamine infusions. Justin’s passion and commitment is to bring this life-saving treatment to Canadians who currently are suffering from major mood disorders and chronic mental-health conditions to provide a new range of opportunities to this population that is often plagued with hopelessness.
Like so many others, I had tried multiple antidepressant medications only to have a partial response or no response at all. I had dealt with my depression that way for over 20 years. It was when an unrelenting bout hit me in 2016 that I knew I had to find something new. I discovered intravenous ketamine infusions in the United States and I remember before my first infusion at a clinic in New York, I was so nervous and desperately hoped it would work. To say it was transformative is to understate it. The heaviness in my head and body dissolved and I felt a lightness that I had not felt in years. I was astounded. It was at that point I vowed that I would bring this treatment to our country.